Background: Breast cancer is not only the most popular in women but is also one of the main causes of death among them in many countries. In Hanoi 1999, the prevalence of breast cancer was 21.8 per 100,000 of the population and was the main cause of death in women. In Ho Chi Minh city that prevalence was 17.1 per 100,000 of the population and was the second highest cause of death in women. Objectives: To assess the value of X-ray mammography and cytopathology test for breast cancer diagnosis of early stage Tis and T1. Subjects and method: A retrospective study was conducted among 103 breast cancer patients with malignant tumor size \uf0a32cm, who were admitted to K Hospital and Thanh Nhan Hospital from 01/2003 to 02/2008. Results:Breast malignant tumor was usually found most frequently at the upper outer quadrant. Around 86.4% of patients who were suspected with malignant lesion by X-ray mammography. Using biopsy test for breast cancer diagnosis, the results shows that 78.6% of patients were positive, 15.6% of cases were suspected and 5.8% had wrong diagnosis. Pathologic classifications were as followed: invasive lobular carcinoma: 78.6%, intraductal carcinoma in situ (Tis): 4.9%. Conclusion: X-ray mammography and cytopathology test are useful tools for the diagnosis of breast cancer.
X-ray mammography ; cytopathology test ; breast cancer ; Tis ; T1

OBJECTIVETo study the inhibition of maxizyme (Mz) directed against the mutant-type p53 gene (mtp53) at codon 249 in exon 7 (AGG --> AGT) both in cell-free system and in MHCC97 cell lines.

METHODSMaxizyme and control mutant maxizyme (G5 --> A5) were designed by computer and cloned into the eukaryotic expression vector pBSKneoU6 (pU6Mz, pU6asMz). Mz was driven by T7 RNA polymerase promoter in vitro. In the cell lines, U6 promoter was driven by RNA PolIII. The mutant type p53 gene fragment was cloned into the pGEM-T vector under the T7 promoter control. The 32P-labeled mtp53 transcript was the target RNA. Cold maxizyme transcripts were incubated with 32P-labeled target RNA in vitro. pU6Mz was introduced into MHCC97 cells by Lipofectamine2000 and mtp53 expression was analyzed by RT-PCR and Western blot.

RESULTSIn vitro cleavage showed that pU6Mz was very active with cleavage efficiency of 42% while pU6asMz was not. The wild type p53 was not cleaved. Partial down-regulation of mtp53 mRNA and mtp53 protein were observed in MHCC97 cells transfected with pU6Mz but not those with pU6asMz. The proliferation of MHCC cells was inhibited by MTT analysis.

CONCLUSIONOur findings suggest that the chimeric U6 maxizyme against the mtp53 is a new promising gene therapeutic agent in treating hepatocellular carcinoma.

Carcinoma, Hepatocellular ; genetics ; Cell Line, Tumor ; Genetic Therapy ; methods ; Genetic Vectors ; Humans ; Liver Neoplasms ; genetics ; Nucleic Acid Conformation ; Point Mutation ; Protein Conformation ; RNA, Catalytic ; RNA, Messenger ; chemical synthesis ; metabolism ; Recombinant Fusion Proteins ; Ribonuclease T1 ; pharmacology ; Tumor Suppressor Protein p53 ; genetics

There is still a strong need for new treatment strategies that will maintain remission and prolong survival in patients with acute lymphoblastic leukemia (ALL). The glutathione-S-transferase (GST) enzymes, which are coded by highly polymorphic genes, have been associated with the risk of developing cancer and were found to regulate effect of cancer treatment drugs.
OBJECTIVES: The present study determines the association of GSTM1, GSTP1 and GSTT1 polymorphisms and treatment response in terms of occurrence of adverse events and relapse in ALL in Filipino children.
METHODS: This is a follow up study on the 2007 investigation done by Alcausin et al. which determined the association of the GST P1, M1, and T1 polymorphisms and occurrence of ALL. Four-year follow-up data were available for 46 out of the 50 patients from January 2007 to May 2011. Odds ratios (OR) as measures of association of GST M1, P1 and T1 gene polymorphisms with treatment outcomes were estimated at 95% confidence interval.
RESULTS: Results show a trend towards predisposition to elevation of liver enzymes in patients with GSTT1 and GSTP1 mutant genotypes showing an OR (95% Cl) of 2.0 (0.62-6.49). The presence of GSTM1 null genotype showed a trend towards protection from occurrence of relapse basing on both crude and adjusted ORs, 0.58 (0.16-2.07) and 0.23 (0.05-1.20), respectively. However, these results are not statistically significant.
CONCLUSION: The GSTP1 heterozygous genotype conferred increased predisposition to elevation of liver enzymes while the GSTT1 null genotype was shown to be a possible risk factor towards the occurrence of both infection and elevation of liver enzymes during chemotherapy. Furthermore, the GSTM1 null genotype appears to be protective from occurrence of relapse. It is recommended to do similar large-scale studies in the future to obtain more conclusive results.

Human ; Male ; Female ; Child ; Child Preschool ; Child ; Confidence Intervals ; Follow-up Studies ; Genotype ; Glutathione ; Glutathione S-transferase Pi ; Glutathione Transferase ; Liver ; Precursor Cell Lymphoblastic Leukemia-lymphoma ; Recurrence ; Treatment Outcome ; Glutathione S-transferase M1 ; Glutathione S-transferase T1